PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News:

SpineGuard (Paris:ALSGD) (FR0011464452 – ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, reminds its shareholders that the Annual Shareholder's Meeting will be held on Wednesday, June 8, 2022 at 10:00 am at the offices of the law firm Ashurst Paris, located at 18 square Edouard VII, 75009 Paris, and details its terms and conditions as well as its letter to shareholders.

Voting procedures

Shareholders will be able to attend the Shareholders' Meeting in person or to vote remotely, before the Shareholders' Meeting via the "Votaccess" e-platform, or by mail or by proxy, in accordance with the procedures indicated in the bulletin des Annonces Légales Obligatoires dated on May 2, 2022 (French).

e-voting using the "Votaccess" e-platform will be available from 09:00 am CEST today May 20. If your broker or bank is a member of the Votaccess e-platform, access is made using the same regular login and password used to access your broker / bank e-services. The Votaccess e-platform will close on Tuesday, June 7 at 03:00 pm CEST.

The possibility of voting or giving a proxy by mail will end on June 3, 2022 (end of the deadline for receiving voting forms).

Documents including the shareholders' brochure ('brochure de convocation' in French only) and the voting form are available at the following links:

• Voting Form
• Shareholders' Brochure (French)

All documents related to this Shareholder's Meeting are available on SpineGuard's website, www.spineguard.com, in the Investors/General Meetings section.

More on Colorado Desk

• Always Ontime: Chaos City - Super Hero Graphic Novel with Neal Adams Cover Launches from Panopolis Metaverse
• New Hampshire Becomes the 15th State to Require Personal Finance as a Core Academic Subject
• Virtual Workplace Platform Developer REACH Expands Executive Team, Positioning the Company to Drive International Growth
• ACRE Provides $43.5M Loan for 'Connect at First Creek' Development in Denver, Colo.
• Wilbur-Ellis Partners with Guardian Agriculture in Multi-Million Dollar Agreement to Bring Autonomous Aerial Application to Growers Across America

For any questions regarding voting procedures, shareholders may contact the Investor Relations team by e-mail at the following address: spineguard@newcap.eu

Should the required quorum not be met, a second Meeting would be called for June 30, 2022 at 10:00am CEST, at the offices of the law firm Ashurst Paris, located at 18 square Edouard VII, 75009 Paris

Shareholders are reminded that the AMF strongly encourages them to exercise their voting rights, which is a fundamental prerogative of the shareholder.

Letter to shareholders

SpineGuard presents its letter to shareholders

"The growing interest triggered by our latest advances offers real value creation perspectives. It is stimulating the entire SpineGuard team who strives to reveal the full potential of the DSG technology, unique in its capacity to secure and streamline the placement of implants in bone while minimizing the recourse to X-rays," said SpineGuard's Co-founders, Pierre Jérôme, CEO, and Stéphane Bette, Deputy CEO.

Read the full letter to shareholders HERE

About SpineGuard®

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 80,000 surgical procedures worldwide. Seventeen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these solid fundamentals and several strategic partnerships, SpineGuard has expanded its technology platform in a disruptive innovation: the « smart » pedicle screw launched late 2017 and is broadening the scope of applications in dental implantology and surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer.

More on Colorado Desk

• Health Advisory: Protecting Yourself and Others from Monkeypox
• Primus Aerospace Acquires Raloid Corporation
• Kindle FREE June 28-29: Powerful new memoir from Santa Molina-Marshall poised to help heal abuse victims through inspiring storytelling
• GoodLoan.io announces new program to unlock up to $500,000 for Home Equity Investment
• Colorado Springs: Lane closure on Circle Drive bridges due to maintenance project

For further information, visit www.spineguard.com

Disclaimer

The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

Contacts

SpineGuard
Pierre Jérôme
CEO & Chairman
Tel: +33 1 45 18 45 19
p.jerome@spineguard.com

SpineGuard
Manuel Lanfossi
CFO
Tel: +33 1 45 18 45 19
m.lanfossi@spineguard.com

NewCap
Investor Relations & Financial Communication
Mathilde Bohin / Pierre Laurent
Tel.: +33 1 44 71 94 94
spineguard@newcap.eu

---

Show All News | Report Violation